In parallel, CL probiotics, which act as selective intestinal FXR agonists, may improve BA metabolism and transport by regulating the FXR-FGF15 pathway, thereby alleviating NAFLD in high-fat diet FXR−/− mice. This evidence concerns the gene NR1H4 and metabolic dysfunction-associated steatotic liver disease.